This post is not the latest immunisation update and therefore may contain information or advice that is out of date. Please see our most recent update here.
This fact sheet for patients outlines when a vaccine may not be recommended, or when vaccinations should be postponed.
ATAGI now recommendsPfizer COVID-19 vaccine for use as a booster dose in adolescents aged 16-17 years. Eligible 16 to 17 year olds are able to receive a COVID-19 booster as ATAGI extends the recommendation of a booster vaccination for all people aged 16 years and above from 3 months after receiving their last primary vaccination dose.
The AIR042A report has undergone enhancements. Using the practice’s PIP ID (Practice Incentives Program ID), providers can now identify all patients due for a booster vaccine. Practices are encouraged to recall all patients due for their booster vaccine and utilise their excess COVID-19 vaccines prior to defrost expiry.
The Australian Technical Advisory Group on Immunisation (ATAGI) has released guidance that summarises ‘up-to-date’ vaccination status as defined in their clinical guidance for the use of COVID-19 vaccines. Key points include:
In its advice, ATAGI acknowledges that this change in definition of up-to-date status for COVID-19 vaccines may impact the status of an individual’s COVID-19 immunisation certificate, and sufficient time should be provided to support implementation of changes. ATAGI has recommended they be made effective by the end of March 2022
On 10 February 2022, National Cabinet endorsed the AHPPC recommendation to mandate COVID-19 booster vaccinations in residential aged care facilities. All state and territory governments will implement this decision on mandatory booster doses for residential aged care workers consistent with arrangements already in place through state and territory public health orders and equivalent arrangements.
The Practice Incentives Program (PIP) COVID-19 in-reach vaccination payment is a time-limited payment to support general practices that undertake in-reach COVID-19 vaccination services for residential aged care and disability support workers in their workplace.
This payment is only available for Medicare Benefits Schedule (MBS) COVID-19 vaccine suitability assessment services (for primary vaccine course and subsequent booster vaccine doses) that are administered via an in-reach COVID-19 vaccination clinic between 29 April 2021 to 30 June 2022. See payment guidelines.
What has changed in the ATAGI recommendations on the use of a third primary dose of COVID-19 vaccine in individuals who are severely immunocompromised:
On 7 February 2022, the Prime Minister announced that from 21 February Australia’s international borders will be open to all individuals with a valid visa and proof of receiving two doses of an approved vaccination. Unvaccinated travellers will still need to apply for a travel exemption and will be required to undergo hotel quarantine on arrival if granted permission to enter the country.
On 21 January 2022, the Government opened a targeted Expression of Interest (EOI) process to identify participating general practices interested in administering the Novavax vaccine.
The interested primary care sites have been split into two tranches, for the first deliveries: Tranche 1 sites are expected to commence Novavax from the 21 February 2022, and Tranche 2 sites from the 28 February 2022.
Novavax COVID-19 vaccine has also been included in the standing Expression of Interest open for all general practices interested in expanding their participation in the Program. Email immunisation@cesphn.com.au for EOI form.
On 8 February 2022, the Therapeutic Goods Administration (TGA) provisionally approved the Vaxzeria (AstraZeneca) vaccine as a booster vaccine for individuals aged 18 years and above. Read ATAGI’s advice on the type of vaccine recommended for booster doses. Important things to note:
A new fact sheet has been developed on 14 Feb 2022, providing information on how to manage needle phobia for adults. Information for adults with a needle phobia.
The TGA has announced that Gamaleya Sputnik V is a recognised vaccine and can now be recorded on the Australian Immunisation Register (AIR). See AIR vaccine code formats.
The Services Australia website lists the COVID-19 vaccines approved or recognised by the TGA that can be recorded on AIR. Individuals who had a recognised COVID vaccine overseas on or after 1 March 2020, can have it recorded on AIR.
| TGA approved | TGA recognised |
| • AstraZeneca Vaxzevria • Pfizer/Biontech Comirnaty • Moderna Spikevax • Novavax NUVAXOVID • Janssen-Cilag COVID Vaccine. | • AstraZeneca COVISHIELD • Bharat Biotech Covaxin • Gamaleya Sputnik V • Sinopharm BBIBP-CorV • Sinovac Coronavac. |
People who have received either a first dose or a full course of a COVID-19 vaccine that is not TGA-approved or TGA-recognised should be offered two doses of an alternative TGA-approved vaccine brand available in Australia to be considered fully vaccinated.
People should begin their full course of a TGA-approved or recognised COVID-19 vaccination at an interval of 4 to 12 weeks after their most recent COVID-19 vaccine dose. A longer interval is acceptable if the vaccine course cannot be started during this time frame. See ATAGI advice
Join the latest COVID-19 vaccine live stream update for GPs. The panel will provide latest key updates and answer participants’ questions live about the COVID-19 vaccine rollout.
Details: Thursday 17 February 2022, 11:30am (AEDT) | Click link to join
Catch up on previous webinars.
Key points of the updated NSW Pharmacist Vaccination Standards include:
The national rollout for VCF Connect started on 2 February2022, and will continue in a series of tranches until all primary care vaccination providers are contacted. Registration emails are planned to be complete by 28 February 2022. VCF Connect Registration emails are sent to the authorised contacts on the COVID 19 Vaccine Administrative System (CVAS).
All vaccine providers must register for VCF Connect as the current manual processes for updating the Vaccine Clinic Finder will cease from 31 March 2022. If vaccination providers have further questions, please encourage them to contact CV19.Products@health.gov.au or 1800 316 375.
%MCEPASTEBIN%
Speak up for the community: Do you know someone who could give great input about health needs and services? voices4health is the place where people living in central and eastern Sydney can contribute to decision-making about health needs and services in the area where they live. This is a place…
Stay alert for meningococcal symptoms NSW Health is urging health professionals to be on alert for symptoms of meningococcal disease and act immediately if they appear after the notification of three recent cases. So far this year, there have been 19 cases of meningococcal disease reported in NSW. The majority…
Nominate or Apply for the 2023 CESPHN Primary Health Awards: The annual Central and Eastern Sydney PHN (CESPHN) Health Awards recognises primary health care professionals and organisations that have provided exceptional service or an outstanding contribution to primary health care in the Central and Eastern region of Sydney during the…
Speak up for the Community: Are you interested in having a say about health needs and health services in your area? voices4health is the place where people living in central and eastern Sydney can contribute to decision-making about health needs and services in the area where they live. This is…
FIVE QUESTIONS is where we ask members of the community to talk about how they stay HEALTHY. General Manager First Nations Fashion + Design and Wiradjuri Woman living on Dharawal Country Emma Griggs (pictured below at the recent Australian Fashion Week 2023 at Carriageworks, Gadigal land), shared this: 1. What did…
Study Invitation for Parents of Children with Eczema: A research team at Western Sydney University is seeking parents for a study exploring their perspectives around topical steroid use for eczema management. Participants will be involved in a virtual (via Zoom or telephone) interview, which will take up to 1 hour….
